Mylan
Also known as: MLV | MYLAN | MYLAN ASI | MYLAN BERTEK | Mylan Bertek Pharmaceuticals | Mylan Bertek Pharmaceuticals Inc. | Mylan GmbH | MYLAN GMBH | Mylan Inc. | MYLAN INSTITUTIONAL | MYLAN IRELAND LTD | Mylan Laboratories | MYLAN LABS | MYLAN LABS INC | MYLAN LABS LTD | MYLAN PHARMA | Mylan Pharmaceuitcals Inc. | Mylan Pharmaceutials | Mylan Pharmaceuticals | Mylan Pharmaceuticals Inc | Mylan Pharmaceuticals Inc. | MYLAN PHARMACEUTICALS INC | MYLAN PHARMACEUTICALS INC A VIATRIS CO | Mylan Pharma UK Ltd. | MYLAN PHARMS INC | MYLAN SPCLT VIATRIS | MYLAN SPECIALITY LP | Mylan Specialty L.P. | Mylan Specialty, LP | MYLAN SPECLT | Mylan (Taiwan) Ltd | MYLAN TECHNOLOGIES | Mylan Technologies Inc. | MYLAN TECH VIATRIS | MYLAN TEORANTA | PVT FORM | Synerx Pharma, LLC | Viatris Pharmaceuticals Co., Ltd.
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1999First marketed drug
Jan 1, 1961First NDA
Jun 5, 1965Last known activity
Jun 3, 2026
Timeline
1960s
- Jan 1, 1961
Mylan— Founded
- Jan 24, 1969
mafenide acetate— NDA Organization
1990s
- Apr 1, 1994
doxepin— NDA Secondary Org
- Feb 28, 1996
UDL Laboratories— Acquired
- Jun 25, 1998
Penederm— Acquired
2000s
- Jan 1, 2007
Matrix Laboratories Limited— Acquired
- May 14, 2007
Alphapharm— Acquired
- Jun 1, 2007
Dey— Acquired
- Jul 29, 2008
Somerset Pharmaceuticals— Acquired
2010s
- Jul 15, 2010
Bioniche Pharma Group— Acquired
- Feb 24, 2011
Apothecon— Acquired
- Dec 4, 2013
Agila Specialties— Acquired
- Feb 2, 2015
Jai Pharma Ltd.— Acquired
- Feb 10, 2016
Meda Pharmaceuticals— Acquired
- Aug 5, 2016
Meda— Acquired
- Apr 7, 2017
atracurium— Marketing Organization
Drugs by trial phase (172 distinct, 339 trials)
Phase 4 (14 own, 17 via acquisition)
Phase 3 (25 own, 32 via acquisition)
Phase 2 (7 own, 9 via acquisition)
Phase 1 (61 own, 4 via acquisition)
Other trials (0 own, 3 via acquisition)
Indications
Approved for
- Anemia
- Bronchitis, Chronic
- Burns
- Candidiasis, Vulvovaginal
- Colitis, Ulcerative
- Conjunctivitis, Allergic
- Crohn Disease
- Cystinosis
- Cystitis, Interstitial
- Erectile Dysfunction
- Herpes Labialis
- Muscular Diseases
- Pain
- Parkinson Disease
- Pneumonia, Bacterial
- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Seasonal
- Rhinitis, Vasomotor
- Spasm
- Tinea
- Tinea Pedis
- Tinea Versicolor
Studied for
- Acquired Immunodeficiency Syndrome
- Acute Pain
- Alzheimer Disease
- Arthritis, Psoriatic
- Asthma
- Atrophic Vaginitis
- Atrophy
- Breast Neoplasms
- Burns
- Chemotherapy-Induced Febrile Neutropenia
- Cognitive Dysfunction
- Congenital Abnormalities
- Coronavirus Infections
- Dermatitis
- Dermatitis, Atopic
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Eczema
- Edema
- Febrile Neutropenia
- Heart Defects, Congenital
- Heart Diseases
- Hepatic Insufficiency
- HIV Infections
- Hyperglycemia
- Hypertension
- Liver Failure
- Lung Diseases
- Lung Diseases, Obstructive
- Macular Edema
- Malnutrition
- Mushroom Poisoning
- Neutropenia
- Osteoarthritis
- Osteoarthritis, Knee
- Parkinson Disease
- Poisoning
- Psoriasis
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Valve Insufficiency
- Respiratory Insufficiency
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Signs and Symptoms
- Tinea
- Tinea Pedis
- Tissue Adhesions
- Vaginitis
- Wounds and Injuries
Marketed drugs (577)
Subsidiaries (12 direct, 20 total across the full acquisition tree)
- Agila Specialties
- Alphapharm
- Apothecon
- Bioniche Pharma Group
- Dey
- Jai Pharma Ltd.
- Matrix Laboratories Limited
- Meda
- Meda Pharmaceuticals
- Penederm
- Somerset Pharmaceuticals
- UDL Laboratories
- Acton Pharmaceuticals L2
- Alaven L2
- Medpointe L2
- Rottapharm L2
- Viatris L2
- Carter-Wallace L3
- Madaus Inc L3
- Oyster Point Pharma, Inc. L3
Recent trials (50)
- NCT07266090Lead sponsorPhase 2Nov 28, 2025
- NCT06672016Lead sponsorPhase 3Dec 31, 2024
- NCT06215820Lead sponsorPhase 3Dec 29, 2023
- NCT06215859Lead sponsorPhase 3Dec 29, 2023
- NCT06048536Lead sponsorPhase 2Mar 7, 2023
- NCT05630872CollaboratorPhase 2Feb 6, 2023
- NCT05637515CollaboratorPhase 3Nov 21, 2022
- NCT05317312Lead sponsorPhase 2Mar 31, 2022
- NCT05165485CollaboratorPhase 4Dec 31, 2021
- NCT05139121CollaboratorPhase 3Oct 26, 2021
- NCT05139121Lead sponsorPhase 3Oct 26, 2021
- NCT05207111Lead sponsorPhase 1Sep 23, 2021
- NCT05046795CollaboratorPhase 3Sep 15, 2021
- NCT05046795Lead sponsorPhase 3Sep 15, 2021
- NCT05046795Study directorPhase 3Sep 15, 2021
Details
- Founded
- White Sulphur Springs, WV, US Jan 1, 1961
- First NDA
- Jun 5, 1965
- Last known activity
- Jun 3, 2026
Designations held
- Orphan drug
- Fast track
- Priority review